Correlation of [
Enzalutamide
Monitoring response.
PSMA PET
Prostate cancer
Journal
European journal of nuclear medicine and molecular imaging
ISSN: 1619-7089
Titre abrégé: Eur J Nucl Med Mol Imaging
Pays: Germany
ID NLM: 101140988
Informations de publication
Date de publication:
29 Aug 2024
29 Aug 2024
Historique:
received:
26
06
2024
accepted:
12
08
2024
medline:
31
8
2024
pubmed:
31
8
2024
entrez:
29
8
2024
Statut:
aheadofprint
Résumé
to assess the utility of response monitoring to enzalutamide by using [ patients underwent [ 69 patients were considered fully evaluable. We observed 47.8% of concordance between [68Ga]Ga-PSMA PET and PSA monitoring at 3 months after starting enzalutamide. For discordant cases, the PSA reduction has a weak impact on PFS and a significant impact on OS in PET-NR patients, whilst this change has no impact either for PFS and OS in PET-R ones. [
Identifiants
pubmed: 39207484
doi: 10.1007/s00259-024-06887-4
pii: 10.1007/s00259-024-06887-4
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Subventions
Organisme : Ricerca Corrente by the Italian Ministry of Health.
ID : Ricerca Corrente by the Italian Ministry of Health.
Informations de copyright
© 2024. The Author(s).
Références
Survival Rates for Prostate Cancer. https://www.cancer.org/cancer/prostate-cancer/detection-diagnosis-staging/survival-rates.html accessed on 1st June 2024.
Miyahira AK, Soule HR. The history of Prostate-Specific Membrane Antigen as a theranostic target in prostate Cancer: the cornerstone role of the prostate Cancer Foundation. J Nucl Med. 2022;63(3):331–8. https://doi.org/10.2967/jnumed.121.262997 .
doi: 10.2967/jnumed.121.262997
pubmed: 34675109
Israeli RS, Powell CT, Corr JG, Fair WR, Heston WD. Expression of the prostate-specific membrane antigen. Cancer Res. 1994;54(7):1807–11.
pubmed: 7511053
Silver DA, Pellicer I, Fair WR, Heston WD, Cordon-Cardo C. Prostate-specific membrane antigen expression in normal and malignant human tissues. Clin Cancer Res. 1997;3(1):81–5.
pubmed: 9815541
Farolfi A, Calderoni L, Mattana F, Mei R, Telo S, Fanti S, Castellucci P. Current and emerging clinical applications of PSMA PET Diagnostic imaging for prostate Cancer. J Nucl Med. 2021;62(5):596–604.
doi: 10.2967/jnumed.120.257238
pubmed: 33712536
Grubmüller B, Rasul S, Baltzer P, Fajkovic H, D’Andrea D, Berndl F, et al. Response assessment using [68 Ga]Ga-PSMA ligand PET in patients undergoing systemic therapy for metastatic castration-resistant prostate cancer. Prostate. 2020;80(1):74–82.
doi: 10.1002/pros.23919
pubmed: 31614001
Alongi P, Laudicella R, Lanzafame H, Farolfi A, Mapelli P, Picchio M, et al. PSMA and Choline PET for the Assessment of response to therapy and survival outcomes in prostate Cancer patients: a systematic review from the literature. Cancers (Basel). 2022;14(7):1770.
doi: 10.3390/cancers14071770
pubmed: 35406542
Scher HI, Fizazi K, Saad F, Taplin ME, Sternberg CN, Miller K, et al. AFFIRM investigators. Increased survival with enzalutamide in prostate cancer after chemotherapy. N Engl J Med. 2012;367(13):1187–97.
doi: 10.1056/NEJMoa1207506
pubmed: 22894553
Beer TM, Armstrong AJ, Rathkopf DE, Loriot Y, Sternberg CN, Higano CS, et al. PREVAIL investigators. Enzalutamide in metastatic prostate cancer before chemotherapy. N Engl J Med. 2014;371(5):424–33.
doi: 10.1056/NEJMoa1405095
pubmed: 24881730
pmcid: 4418931
Sternberg CN. Enzalutamide, an oral androgen receptor inhibitor for treatment of castration-resistant prostate cancer. Future Oncol. 2019;15(13):1437–57.
doi: 10.2217/fon-2018-0940
pubmed: 30848157
Rosar F, Dewes S, Ries M, Schaefer A, Khreish F, Maus S, et al. New insights in the paradigm of upregulation of tumoral PSMA expression by androgen receptor blockade: Enzalutamide induces PSMA upregulation in castration-resistant prostate cancer even in patients having previously progressed on enzalutamide. Eur J Nucl Med Mol Imaging. 2020;47(3):687–94.
doi: 10.1007/s00259-019-04674-0
pubmed: 31901103
Caffo O, Maines F, Donner D, Veccia A, Chierichetti F, Galligioni E. Impact of enzalutamide administration on primary prostate cancer volume: a metabolic evaluation by choline positron emission tomography in castration-resistant prostate cancer patients. Clin Genitourin Cancer. 2014;12(5):312–6.
doi: 10.1016/j.clgc.2014.03.004
pubmed: 24806400
Maines F, Caffo O, Donner D, Sperduti I, Bria E, Veccia A, et al. Serial 18F-choline-PET imaging in patients receiving enzalutamide for metastatic castration-resistant prostate cancer: response assessment and imaging biomarkers. Future Oncol. 2016;12(3):333–42.
doi: 10.2217/fon.15.277
pubmed: 26768648
De Giorgi U, Caroli P, Scarpi E, Conteduca V, Burgio SL, Menna C, et al. (18)F-Fluorocholine PET/CT for early response assessment in patients with metastatic castration-resistant prostate cancer treated with enzalutamide. Eur J Nucl Med Mol Imaging. 2015;42(8):1276–83.
doi: 10.1007/s00259-015-3042-5
pubmed: 25808631
Plouznikoff N, Artigas C, Sideris S, Martinez Chanza N, Gil T, et al. Evaluation of PSMA expression changes on PET/CT before and after initiation of novel antiandrogen drugs (enzalutamide or abiraterone) in metastatic castration-resistant prostate cancer patients. Ann Nucl Med. 2019;33(12):945–54.
doi: 10.1007/s12149-019-01404-2
pubmed: 31587172
Zukotynski KA, Emmenegger U, Hotte S, Kapoor A, Fu W, Blackford AL, et al. Prospective, single-arm trial evaluating changes in uptake patterns on prostate-specific membrane Antigen-targeted 18F-DCFPyL PET/CT in patients with castration-resistant prostate Cancer starting Abiraterone or Enzalutamide. J Nucl Med. 2021;62(10):1430–7.
doi: 10.2967/jnumed.120.259069
pubmed: 33608426
pmcid: 8724901
Shagera QA, Karfis I, Kristanto P, Spyridon S, Diamand R, Santapau A, et al. PSMA PET/CT for Response Assessment and Overall Survival Prediction in patients with metastatic castration-resistant prostate Cancer treated with androgen receptor pathway inhibitors. J Nucl Med. 2023;64(12):1869–75.
doi: 10.2967/jnumed.123.265874
pubmed: 37770114
Sonni I, Gafita A, Unterrainer LM, Alano RM, Lira S, Shen J, et al. Effects of novel androgen receptor signaling inhibitors on PSMA PET signal intensity in patients with castrate-resistant prostate cancer: a prospective exploratory serial imaging study. EJNMMI Res. 2023;13(1):95.
doi: 10.1186/s13550-023-01048-4
pubmed: 37902861
pmcid: 10616012
Young H, Baum R, Cremerius U, Herholz K, Hoekstra O, Lammertsma AA, et al. Measurement of clinical and subclinical tumour response using [18F]-fluorodeoxyglucose and positron emission tomography: review and 1999 EORTC recommendations. European Organization for Research and Treatment of Cancer (EORTC) PET Study Group. Eur J Cancer. 1999;35(13):1773–82.
doi: 10.1016/S0959-8049(99)00229-4
pubmed: 10673991
Telli TA, Ozguven S, Alan O, Filizoglu N, Ozturk MA, Sariyar N, et al. Role of baseline 68Ga-PSMA PET/CT-derived whole-body volumetric parameters in predicting survival outcomes of metastatic castration-resistant prostate cancer patients receiving first-line treatment. Ann Nucl Med. 2022;36(11):964–75.
doi: 10.1007/s12149-022-01785-x
pubmed: 35997890
Can C, Gündoğan C, Yildirim OA, Poyraz K, Güzel Y, Kömek H. Role of 68Ga-PSMA PET/CT parameters in treatment evaluation and survival prediction in prostate cancer patients compared with biochemical response assessment. Hell J Nucl Med. 2021 Jan-Apr;24(1):25–35.
Güzel Y, Kömek H, Can C, Kaplan İ, Akdeniz N, Kepenek F, Gündoğan C. Role of volumetric parameters obtained from 68 Ga-PSMA PET/CT and 18F-FDG PET/CT in predicting overall survival in patients with mCRPC receiving taxane therapy. Ann Nucl Med. 2023;37(9):517–27.
doi: 10.1007/s12149-023-01854-9
pubmed: 37332068
Altavilla A, Caroli P, Giunta EF, Scarpi E, Rossetti V, Casadei C et al. Impact of 68Ga-PSMA PET/CT in patients with metastatic castration-resistant prostate cancer (mCRPC) treated with enzalutamide. Journal of Clinical Oncology. https://doi.org/10.1200/JCO.2023.41.6_suppl.48
Komek H, Can C, Yilmaz U, Altindag S. Prognostic value of 68 Ga PSMA I&T PET/CT SUV parameters on survival outcome in advanced prostat cancer. Ann Nucl Med. 2018;32(8):542–52.
doi: 10.1007/s12149-018-1277-5
pubmed: 30006752
Seifert R, Rasul S, Seitzer K, Eveslage M, Rahbar Nikoukar L, et al. A prognostic risk score for prostate Cancer based on PSMA PET-derived organ-specific Tumor volumes. Radiology. 2023 Apr;18:222010.
Buteau JP, Martin AJ, Emmett L, Iravani A, Sandhu S, Joshua AM, TheraP Trial Investigators and the Australian and New Zealand Urogenital and Prostate Cancer Trials Group, et al. PSMA and FDG-PET as predictive and prognostic biomarkers in patients given [177Lu]Lu-PSMA-617 versus cabazitaxel for metastatic castration-resistant prostate cancer (TheraP): a biomarker analysis from a randomised, open-label, phase 2 trial. Lancet Oncol. 2022;23(11):1389–97.
doi: 10.1016/S1470-2045(22)00605-2
pubmed: 36261050
Groener D, Schneider S, Baumgarten J, Happel C, Klimek K, Mader N, et al. Baseline [68Ga]Ga-PSMA-11 PET/CT before [177Lu]Lu-PSMA-617 Radioligand Therapy: value of PSMA-Uptake thresholds in Predicting Targetable lesions. Cancers (Basel). 2023;15(2):473.
doi: 10.3390/cancers15020473
pubmed: 36672421
Gafita A, Rauscher I, Weber M, Hadaschik B, Wang H, Armstrong WR, et al. Novel Framework for treatment response evaluation using PSMA PET/CT in patients with metastatic castration-resistant prostate Cancer (RECIP 1.0): an International Multicenter Study. J Nucl Med. 2022;63(11):1651–8.
pubmed: 35422442
pmcid: 9635677
Seitz AK, Rauscher I, Haller B, Krönke M, Luther S, Heck MM, et al. Preliminary results on response assessment using 68Ga-HBED-CC-PSMA PET/CT in patients with metastatic prostate cancer undergoing docetaxel chemotherapy. Eur J Nucl Med Mol Imaging. 2018;45(4):602–12.
doi: 10.1007/s00259-017-3887-x
pubmed: 29185010
Kranzbühler B, Salemi S, Umbricht CA, Müller C, Burger IA, Sulser T, Eberli D. Pharmacological upregulation of prostate-specific membrane antigen (PSMA) expression in prostate cancer cells. Prostate. 2018;78(10):758–65.
doi: 10.1002/pros.23522
pubmed: 29633296
Aggarwal R, Wei X, Kim W, Small EJ, Ryan CJ, Carroll P, et al. Heterogeneous flare in prostate-specific membrane Antigen Positron Emission Tomography Tracer Uptake with initiation of androgen pathway blockade in metastatic prostate Cancer. Eur Urol Oncol. 2018;1(1):78–82.
doi: 10.1016/j.euo.2018.03.010
pubmed: 31100231
Emmett L, Yin C, Crumbaker M, Hruby G, Kneebone A, Epstein R, et al. Rapid Modulation of PSMA expression by Androgen Deprivation: serial 68Ga-PSMA-11 PET in men with hormone-sensitive and castrate-resistant prostate Cancer commencing androgen blockade. J Nucl Med. 2019;60(7):950–4.
doi: 10.2967/jnumed.118.223099
pubmed: 30552200
Fanti S, Briganti A, Emmett L, Fizazi K, Gillessen S, Goffin K, et al. EAU-EANM Consensus statements on the role of prostate-specific membrane Antigen Positron Emission Tomography/Computed tomography in patients with prostate Cancer and with respect to [177Lu]Lu-PSMA Radioligand Therapy. Eur Urol Oncol. 2022;5(5):530–6.
doi: 10.1016/j.euo.2022.05.003
pubmed: 35697600
Fendler WP, Eiber M, Beheshti M, Bomanji J, Calais J, Ceci F, et al. PSMA PET/CT: joint EANM procedure guideline/SNMMI procedure standard for prostate cancer imaging 2.0. Eur J Nucl Med Mol Imaging. 2023;50(5):1466–86.
doi: 10.1007/s00259-022-06089-w
pubmed: 36604326
pmcid: 10027805
Fanti S, Hadaschik B, Herrmann K. Proposal for systemic-Therapy Response-Assessment Criteria at the Time of PSMA PET/CT imaging: the PSMA PET progression Criteria. J Nucl Med. 2020;61(5):678–82.
doi: 10.2967/jnumed.119.233817
pubmed: 31806774
pmcid: 7198387
Fuerea A, Baciarello G, Patrikidou A, Albigès L, Massard C, Di Palma M, et al. Early PSA response is an independent prognostic factor in patients with metastatic castration-resistant prostate cancer treated with next-generation androgen pathway inhibitors. Eur J Cancer. 2016;61:44–51.
doi: 10.1016/j.ejca.2016.03.070
pubmed: 27151554
Armstrong AJ, Lin P, Higano CS, Iversen P, Sternberg CN, Tombal B, et al. Prognostic Association of Prostate-Specific Antigen Decline with clinical outcomes in men with metastatic castration-resistant prostate Cancer treated with Enzalutamide in a Randomized Clinical Trial. Eur Urol Oncol. 2019;2(6):677–84.
doi: 10.1016/j.euo.2018.11.005
pubmed: 31274110
Scher HI, Morris MJ, Stadler WM, Higano C, Basch E, Fizazi K, Prostate Cancer Clinical Trials Working Group 3, et al. Trial Design and objectives for castration-resistant prostate Cancer: updated recommendations from the prostate Cancer clinical trials Working Group 3. J Clin Oncol. 2016;34(12):1402–18. https://doi.org/10.1200/JCO.2015.64.2702 .
doi: 10.1200/JCO.2015.64.2702
pubmed: 26903579
pmcid: 4872347
Bryce AH, Alumkal JJ, Armstrong A, Higano CS, Iversen P, Sternberg CN, Rathkopf D, Loriot Y, de Bono J, Tombal B, Abhyankar S, Lin P, Krivoshik A, Phung D, Beer TM. Radiographic progression with nonrising PSA in metastatic castration-resistant prostate cancer: post hoc analysis of PREVAIL. Prostate Cancer Prostatic Dis. 2017;20(2):221–7.
doi: 10.1038/pcan.2016.71
pubmed: 28117385
pmcid: 5435962
Han S, Woo S, Kim YI, Lee JL, Wibmer AG, Schoder H, et al. Concordance between Response Assessment using prostate-specific membrane Antigen PET and serum prostate-specific Antigen levels after systemic treatment in patients with metastatic castration resistant prostate Cancer: a systematic review and Meta-analysis. Diagnostics (Basel). 2021;11(4):663.
doi: 10.3390/diagnostics11040663
pubmed: 33917006
FDA approves Pluvicto for metastatic castration-resistant prostate cancer. https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-pluvicto-metastatic-castration-resistant-prostate-cancer accessed on 1st June 2024.